ReviewJournal of neurology2021
Mesenchymal stem cell therapy for ischemic stroke: A look into treatment mechanism and therapeutic potential.
Review in Journal of neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
68 citing papers in PubMed, 2 syntheses or guidelines pooled it, 128 citations in OpenAlex.
- Efficacy and safety of mesenchymal stem cells in patients with acute ischemic stroke: a meta-analysis.BMC neurology · 2024Pooled it
- Neuroprotective Effects of Conditioned Medium of Mesenchymal Stem Cells (MSC-CM) as a Therapy for Ischemic Stroke Recovery: A Systematic Review.Neurochemical research · 2023Pooled it
- Trial
- Intravenous human umbilical cord-derived mesenchymal stem cell transplantation for ischemic stroke (MERIT): A phase 1 trial.Cell reports. Medicine · 2026Article
- The role of stem cells and their engineering strategies in the repair of nerve damage in intracerebral hemorrhage.Cell & bioscience · 2026Review
- Ciprofol attenuates cerebral Ischemia‒reperfusion injury in rats by inhibiting ferroptosis through upregulating AMPK.Scientific reports · 2026Article
- IGF2BP1 Aggravates NLRP3 Inflammasome Activation and Pro-Inflammatory Phenotype in Microglia-like Cells by Promoting TRIM45 Expression.Neurotoxicity research · 2026Article
- Stimuli-Responsive Biomimetic Nanomedicines for Targeted Therapy in Ischemic Stroke: Design Principles, Preclinical Evidence and Translational Challenges.International journal of nanomedicine · 2026Review
- Cost-effectiveness of stem cell therapy versus standard of care for acute and subacute ischemic stroke.PloS one · 2026Article
- Stem cell therapy for stroke: mechanisms, clinical translation, and future perspectives.Frontiers in cellular neuroscience · 2026Review
- Mesenchymal stem cells and the central nervous system: historical perspectives and future directions.Frontiers in molecular neuroscience · 2026Review
- Review
- Extracellular Vesicles as Therapeutic Strategy for Ischemic Stroke.Journal of neurochemistry · 2025Review
- Stem Cells Run Like Clockwork for Stroke Therapeutics.Stem cell reviews and reports · 2025Article
- Systemic administration of allogeneic mesenchymal stem cells attenuates post-resuscitation left ventricular dysfunction in a porcine model of cardiac arrest.Resuscitation · 2025Article
- Targeting CX3CR1 Signaling Dynamics: A Critical Determinant in the Temporal Regulation of Post-Stroke Neurorepair.Brain sciences · 2025Review
- Sirtuins Contribute to the Migraine-Stroke Connection.International journal of molecular sciences · 2025Review
- Mechanisms of Action of Propofol in Modulating Microglial Activation in Ischemic Stroke.Molecules (Basel, Switzerland) · 2025Review
- How neural stem cell therapy promotes brain repair after stroke.Stem cell reports · 2025Review
- Comparative Assessment of Manual Segmentation of Cerebral Infarction Lesions in Experimental Animals Based on Magnetic Resonance Imaging Using Artificial Intelligence.Bulletin of experimental biology and medicine · 2025Article
8 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stroke, a global disease with a high disability rate, has limited options for functional rehabilitation and results in an adverse impact on patients' lives. In recent years, mesenchymal stem cells (MSCs) have become a new focus of treatment owing to their potential for neuroregeneration. MSCs have demonstrated therapeutic efficacy capable of cell migration, angiogenesis, immunomodulation, neuroprotection and neural circuit reconstruction. The paracrine action of MSCs can also exert neurotrophic effects and improve the functional recovery. This review shows the transplantation protocol for MSCs, discusses the potential therapeutic mechanisms, and summarizes clinical trials on MSCs for treating ischemic stroke. The current proofs show that MSC therapy for ischemic stroke is safe and feasible. The timing and optimal dose of MSC administration are the main challenges in its clinical use. Although still under research, MSC therapy has the potential to be a new therapeutic approach for neurological recovery from ischemic stroke in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.